Phase III trial programme, ADJUNCT, investigating liraglutide for the treatment of type 1 diabetes mellitus

Trial Profile

Phase III trial programme, ADJUNCT, investigating liraglutide for the treatment of type 1 diabetes mellitus

Planning
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2013

At a glance

  • Drugs Liraglutide (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms ADJUNCT
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Feb 2013 Planned number of patients changed to 2000.
    • 07 Feb 2013 New trial record
    • 04 Feb 2013 This programme is being conducted with the intention of further expanding the Victoza label, according to a Novo Nordisk media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top